Acquired treatment resistance, whereby patients respond well to primary treatment but eventually develop drug resistance, is common across a range of cancer types. It is particularly problematic in the most common form of ovarian cancer, high-grade serous ovarian cancer, and high-risk endometrial cancer. The Elizabeth Christie lab seeks to:
- identify the mechanisms of acquired treatment resistance that arise in high-grade serous ovarian cancer and high-risk endometrial cancer
- identify treatments that can overcome resistance
- develop tumour-based and circulating tumour DNA biomarkers of resistance
- understand the metastatic processes that occur in high-grade serous ovarian cancer.